Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELVN
HOLDEnliven Therapeutics, Inc. · Healthcare · United States · $3.8B · Avg Vol: $98M/d
COMPANY DESCRIPTION
Enliven Therapeutics, Inc. is a clinical-stage precision oncology company dedicated to discovering and developing highly selective and potent kinase inhibitors. The company's lead candidates target specific mutations in cancers such as chronic myeloid leukemia (CML) and solid tumors. Enliven's competitive advantage is its structure-guided drug design platform, enabling the development of best-in-class therapies with improved efficacy and safety profiles for targeted cancer treatment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 7.1K | — |
| EPS | -0.92 | -2.01 | -1.89 | -1.83 | — | -1.60 | -1.70 | -2.33 | — |
| Shares | 41.1M | 41.3M | 48.9M | 59.4M | +44.6% | 71.4M | — | — | — |
| Debt | 0.3M | 0.3M | 0 | 0.4M | 7.3% | 0.3M | — | — | — |
| Equity | -76.8M | 245.9M | 309.8M | 459.6M | 36.7% | — | — | — | — |
| Op CF | -32.1M | -61.3M | -73.2M | -70.3M | — | -65.5M | — | — | — |
| Inv CF | -0.6M | -148.4M | -36.0M | -173.8M | — | — | — | — | — |
| Fin CF | -1.8M | 234.3M | 133.2M | 218.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELVN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc.(you) | $3.8B | 45 | HOLD |
| MBX | MBX Biosciences, Inc. | $3.0B | 40 | HOLD |
| TVTX | Travere Therapeutics, Inc. | $5.3B | 48 | HOLD |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.5B | 42 | HOLD |
| DYN | Dyne Therapeutics, Inc. | $4.0B | 35 | SELL |
| PTCT | PTC Therapeutics, Inc. | $6.4B | 46 | HOLD |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.9B | 47 | HOLD |
| 0HKF.L | Axsome Therapeutics, Inc. | $7.7B | 45 | HOLD |
| DFTX | Definium Therapeutics, Inc. | $5.7B | 39 | HOLD |
| RLAY | Relay Therapeutics, Inc. | $4.0B | 31 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%